Literature DB >> 2660393

Quinolones in urology.

K T Nielsen1, P O Madsen.   

Abstract

The new quinolones have broad antimicrobial spectra covering all aerobic gram-negative and gram-positive bacteria encountered in urinary tract infections. All are administered orally, some also parenterally, low degree of resistance, few side effects and bacteriological and clinical cure rates similar to or higher than traditional antimicrobials make them especially suitable for treatment of complicated urinary tract infections including bacterial prostatitis. Non-critical use of quinolones in simple infections where standard drugs may be equally effective and safe should be discouraged.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2660393     DOI: 10.1007/bf00262033

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  50 in total

1.  Concentration of pefloxacine in split ejaculates of patients with chronic male accessory gland infection.

Authors:  F H Comhaire
Journal:  J Urol       Date:  1987-10       Impact factor: 7.450

2.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

3.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Oral ciprofloxacin as prophylaxis in transurethral resection of the prostate.

Authors:  D A Murdoch; D F Badenoch; E R Gatchalian
Journal:  Br J Urol       Date:  1987-08

5.  Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women.

Authors:  F Garlando; S Rietiker; M G Täuber; M Flepp; B Meier; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

6.  Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients.

Authors:  D A Leigh; E C Smith; J Marriner
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

7.  Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery.

Authors:  M Grabe; A Forsgren; T Björk; S Hellsten
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

8.  Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora.

Authors:  D A Haase; G K Harding; M J Thomson; J K Kennedy; B A Urias; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

9.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

10.  Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.

Authors:  W H Traub
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

View more
  3 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

2.  Timing, dosing and duration of antimicrobial prophylaxis in urology: a study in guinea pigs with special reference to high-risk conditions.

Authors:  T C Gasser; P O Madsen
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

Review 3.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.